Carl Figdor The Immuno-Universe
At the occasion of Carl being active for 40 years in the field of tumor immunology, he will deliver a lecture on how our knowledge on the functioning of the immune system has vastly improved and how this has led to the introduction of immunotherapy as a promising treatment modality for cancer.read more
Carl Figdor The Immuno-UniverseAt the occasion of Carl Figdor being active for 40 years in the field of tumor immunology, he will deliver a lecture on how our knowledge on the functioning of the immune system has vastly improved and how this has led to the introduction of immunotherapy as a new and promising treatment modality for cancer. In his lecture Carl will discuss the state of the art of immunotherapy, the challenges and obstacles that we must overcome, and his view on how these challenges and obstacles can be tackled. Innovative approaches where nanomaterials will be exploited to build synthetic immune systems, may lead to new treatments in the future. So that even more patients can benefit from immunotherapy.
Date, time and location Jubilee lecture
- Date: 25 October 2019
- Time: 16.15 hrs
- Location: Radboud Universiteit, Academiezaal Aula, Comeniuslaan 2
About the full professorCarl Figdor is professor of Immunology at the Radboud University Medical Center. He obtained his master’s degree Biology in 1979 from the University of Utrecht and his PhD degree Medicine in 1982 from the University of Amsterdam working at the Netherlands Cancer Institute, where he started his own research group. In 1992 Carl became professor in Cell Biophysics at the University of Twente, and in 1994 he moved to the Radboud University Medical Center in Nijmegen to start a new department on Tumor Immunology. Here, he initiated a large translational program exploiting the immune system to fight cancer.
Until 2010, Carl was scientific director of the Radboud Institute for Molecular Life Sciences (RIMLS), a research institute within the domain of molecular mechanisms of disease that became internationally recognized during his leadership In 2006. Carl won the Spinoza Prize, which is also known as ‘the Dutch Nobel Prize’, for his groundbreaking research on the use of immune cells against cancer and for the translation of fundamental research into patient care. His research interests focus on the molecular mechanisms controlling antigen presenting cells, in particular dendritic cells. Carl was one of the first to use dendritic cell therapy in patients. He modified dendritic cells to ‘teach’ a patient’s immune system to recognize tumor cells. Major current research projects include the use of antigen loaded dendritic cell vaccines in the treatment of cancer patients and the generation of synthetic dendritic cells.
Carl Figdor received several prizes and honors, including the Van Loghem Award (1999), Spinoza Prize (2006), Dutch Cancer Foundation research award, the ERC Advanced Grant (2010 and 2019) and the NWO Gravity Grant (2013). He is a member of the Academia Europaea and a member of the Royal Dutch Academy of Arts and Sciences. Carl became a Knight in the Order of the Dutch Lion in 2012.